Condition category
Circulatory System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Stroke is a serious, life-threatening medical condition that usually happens when a blood clot or haemorrhage cuts of the blood supply to an area of the brain. Symptoms vary according to how much of the brain is affected and where in the brain the stroke occurs, but includes paralysis, muscle weakness and speech difficulties. A stroke can also have an impact on the sufferers emotions and can lead to anxiety, depression and personality changes. It is thought that lowering blood pressure quickly after the stroke could have a beneficial effect on a patient’s recovery. Therefore, this study aims to find out whether giving patients who are suspected of having a stroke, a 5mg transdermal glyceryl trinitrate (GTN) patch (a commonly used drug in patients with heart disease) as soon as possible after stroke, and then daily for the next three days, improves outcome.

Who can participate?
Adult patients presenting to paramedics as having a stroke. The stroke should have occurred no more than 4 hours ago and the patients systolic BP >=120 mmHg

What does the study involve?
Participants are randomly allocated into one of two groups. Those in group 1 are given GTN patches for 4 days. Those in group 2 are given sham (dummy) patches for 4 days. The patches are unmarked and are covered with a gauze dressing so that participant, relatives and staff who are not putting the patches on don’t know what treatment has been given. The paramedic and hospital staff putting the patch on do know what treatment the patient has. Paramedics obtain consent and put the first patch on, either in the participant’s home or in the ambulance, before they take the patient to the hospital. The participant has all the care they would normally get for their stroke. In addition, they have a second CT scan on Day 2. They are telephoned 3 months and then 1 year after their stroke and asked various structured questions to determine their recovery. When settled in hospital, participants may be asked to agree to some extra procedures or give extra blood samples for research by a member of the research team. Participants do not need to take part in any of this additional research.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Nottingham City Hospital (UK)

When is the study starting and how long is it expected to run for?
May 2015 to February 2018

Who is funding the study?
British Heart Foundation (UK)

Who is the main contact?
Mrs Diane Havard

Trial website

Contact information



Primary contact

Mrs Diane Havard


Contact details

Nottingham City Hospital
Division of Stroke Medicine
The University of Nottingham
Clinical Sciences Building
Hucknall Road
United Kingdom

Additional identifiers

EudraCT number

2015-000115-40 number

Protocol/serial number


Study information

Scientific title

Rapid intervention with glyceryl trinitrate in hypertensive stroke trial-2 (RIGHT2): assessment of safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, and of the feasibility of a multicentre ambulance-based stroke trial



Study hypothesis

This study aims to find out whether giving patients who are suspected of having a stroke, a 5mg transdermal glyceryl trinitrate (GTN) patch (a commonly used drug in patients with heart disease) as soon as possible after stroke, and then daily for the next three days, improves outcome.

Ethics approval


Study design

Randomised; Interventional; Design type: Treatment

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details to request a patient information sheet


Topic: Stroke; Subtopic: Acute Care; Disease: In hospital study


Transdermal Glyceryl Trinitrate patch 5mg, daily for 4 days or sham patch for 4 days.

Intervention type



Phase III

Drug names

Glyceryl Trinitrate

Primary outcome measure

Death/dependence/independence: 7-level modified Rankin Scale 90 days after stroke

Secondary outcome measures


Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Patients presenting to paramedics in context of 999 ambulance call for ‘stroke’
2. Age 18 years or more (there is no maximum age)
3. ‘Face/Arm/Speech’ Time (FAST) score >1
4. Time <=4 hours of onset
5. Systolic BP >=120 mmHg
6. Have provided informed consent, or a relative/paramedic has provided proxy consent
7. Paramedic is trained in RIGHT2 procedures, is from a participating ambulance station and will take patient to a participating comprehensive/primary stroke centre

Participant type


Age group




Target number of participants

Planned Sample Size: 850; UK Sample Size: 850

Total final enrolment


Participant exclusion criteria

1. Patient at a Nursing or Care Home
2. Glucose (BM stix) <2.5 mmol/l
3. Glasgow Coma Scale <8
4. Witnessed seizure/fit at presentation
5. Known life expectancy <6 months
6. Known to have taken a PDE5 inhibitor, such as sildenafil, in previous day before stroke
7. Known sensitivity to Transiderm Nitro patch
8. Known sensitivity to Duoderm hydrocolloid dressing

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Nottingham City Hospital
Division of Stroke Medicine
United Kingdom

Sponsor information


University of Nottingham

Sponsor details

Research Innovation Services
Kings Meadow Campus
Lenton Lane
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

British Heart Foundation

Alternative name(s)


Funding Body Type

private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)


United Kingdom

Results and Publications

Publication and dissemination plan

The results will be published in February 2019.

Intention to publish date


Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2019 protocol in: (added 28/11/2019)
2019 results in:
2019 baseline characteristics in: (added 22/01/2020)
2019 results in (added 31/03/2020)

Publication citations

Additional files

Editorial Notes

31/03/2020: Publication reference added. 22/01/2020: Publication reference and total final enrolment number added. 28/11/2019: Publication reference added. 11/02/2019: Publication reference added. 07/02/2019: The following changes were made: 1. The overall trial end date was changed from 01/02/2018 to 31/10/2018. 2. The intention to publish date was added. 3. The publication and dissemination plan was added.